Is CRME a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

321 people get CRME articles and Market Currents by email alert.

Get email alerts on CRME »

HEADLINES:

Cardiome Pharma Management Discusses Q1 2013 Results - Earnings Call Transcript
Mon, May 13
Cardiome Reports First Quarter Results

PR Newswire (May 13, 2013)
Cardiome To Present At Bloom Burton & Co. Healthcare Investor Conference

PR Newswire (May 10, 2013)
Cardiome Announces The Addition Of Dr. Steen Juul-Möller As Medical Director, Europe

PR Newswire (Mar 28, 2013)
Cardiome Announces Changes to Senior Management Team

PR Newswire (Mar 26, 2013)
Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Cardiome Shareholders Vote in Favor of Share Consolidation

PR Newswire (Mar 19, 2013)
Cardiome Pharma Management Discusses Q4 2012 Results - Earnings Call Transcript
Fri, Mar 15
Cardiome Reports Fourth Quarter and Full Year 2012 Financial Results

PR Newswire (Mar 15, 2013)
Cardiome to Hold Fourth Quarter and Full Year 2012 Financial Results Conference Call on March 15

PR Newswire (Mar 12, 2013)
Cardiome announces settlement of debt and termination of line of credit with Merck

PR Newswire (Mar 4, 2013)
Cardiome Selects Quintiles To Manage Global Regulatory Affairs And Life Cycle Safety Activities For BRINAVESS™ (Vernakalant Intravenous)

PR Newswire (Feb 4, 2013)
4 Speculative Biotech Stocks To Consider
BuySellShort • Thu, Jan 31 • 28 Comments
VIX - Options Volatility Sonar: Wednesday Recap
Erick McKitterick • Wed, Jan 16 • 12 Comments
Cardiome Shares Remain Low On Merck's Abandonment
Brian L. Wilson • Wed, Dec 19, 2012 • 4 Comments
Cardiome Reaches Agreement With Merck to Retire Debt and Close Line of Credit

GlobeNewswire (Dec 11, 2012)
Cardiome Reports Third Quarter Results

GlobeNewswire (Nov 13, 2012)
NASDAQ Grants Cardiome 180 Day Extension to Regain Compliance With Bid Price Requirement

GlobeNewswire (Oct 31, 2012)
NASDAQ Approves Cardiome's Request to Transfer Its Listing to The NASDAQ Capital Market

GlobeNewswire (Oct 25, 2012)
Merck Successes Create Buying Opportunity
ValueMax • Wed, Oct 10, 2012
Cardiome to Hold Conference Call

GlobeNewswire (Sep 26, 2012)

To learn more about Seeking Alpha Pro, click here.

Cardiome Shares Remain Low On Merck's Abandonment
Brian L. Wilson • Wed, Dec 19, 2012 • 4 Comments
Hedge Fund Bridger Ups Cardiome Pharma Holdings
Market Folly • Tue, Dec 8, 2009
Cardiome Pharma: More Encouraging Trial Results
FP Trading Desk • Wed, Jul 16, 2008 • 1 Comment
Cardiome Pharma: Stock Up 30% on Positive Clinical Trials
FP Trading Desk • Tue, Mar 18, 2008

4 Speculative Biotech Stocks To Consider
BuySellShort • Thu, Jan 31 • 28 Comments
VIX - Options Volatility Sonar: Wednesday Recap
Erick McKitterick • Wed, Jan 16 • 12 Comments
Merck Successes Create Buying Opportunity
ValueMax • Wed, Oct 10, 2012
Diana Containerships: High-Yield Dividend Play With Mid-Term Charters
J Mintzmyer • Tue, Jul 3, 2012 • 27 Comments
Billionaire Julian Robertson Is Getting Cautious
Insider Monkey • Tue, Nov 22, 2011 • 1 Comment
'Beat Up' Biotechs To Buy: Part 1
StockMarketPundits • Tue, Sep 20, 2011
Julian Robertson is Bullish About These Tech, Consumer and Healthcare Stocks
Insider Monkey • Wed, Aug 17, 2011 • 2 Comments
Top Buy and Sell Ideas Based on Wednesday's Biggest Losers - Part 1
GuruFundPicks • Thu, Jul 28, 2011
A Look at 5 Stocks That Closed Higher Tuesday
Alex Shadunsky • Wed, Jul 27, 2011
Julian Robertson's Favorite Stock Picks
Insider Monkey • Tue, Jul 12, 2011 • 2 Comments
5 Magic Formula Names With Market Caps Under $1 Billion
Hedgephone • Thu, May 12, 2011 • 3 Comments
Benefit by Imitating Julian Robertson: Bullish on Commodities, China, And Tech
Insider Monkey • Wed, Mar 30, 2011 • 4 Comments
Goodwill in Asset Value: Its Impact on 33 Stocks
MagicDiligence • Tue, Dec 21, 2010 • 2 Comments
Lilly Antibody Fails in Diabetes Trial: Biotech's Latest Tribulations
The Burrill Report • Sun, Oct 24, 2010
Flat Finish Friday, But Stocks End Week Sharply Lower
Midnight Trader • Fri, Jun 25, 2010 • 4 Comments
25 Momentum Stocks for Tuesday
Option Maestro • Tue, Apr 6, 2010
Hedge Fund Bridger Management Is Bullish on Healthcare
Market Folly • Sun, Feb 28, 2010 • 3 Comments
The Complete List of Canadian Stocks Traded on the Nasdaq
David Hunkar • Mon, Dec 21, 2009 • 3 Comments
Closing Update for Wednesday, August 26: Scrapping Back
Midnight Trader • Wed, Aug 26, 2009 • 2 Comments
Cash for Cardiovascular: Who Might Be Next?
Michael Becker • Wed, Aug 12, 2009 • 1 Comment

Cardiome Reports First Quarter Results

PR Newswire (May 13, 2013)
Cardiome To Present At Bloom Burton & Co. Healthcare Investor Conference

PR Newswire (May 10, 2013)
Cardiome Announces The Addition Of Dr. Steen Juul-Möller As Medical Director, Europe

PR Newswire (Mar 28, 2013)
Cardiome Announces Changes to Senior Management Team

PR Newswire (Mar 26, 2013)
Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Cardiome Shareholders Vote in Favor of Share Consolidation

PR Newswire (Mar 19, 2013)
Cardiome Reports Fourth Quarter and Full Year 2012 Financial Results

PR Newswire (Mar 15, 2013)
Cardiome to Hold Fourth Quarter and Full Year 2012 Financial Results Conference Call on March 15

PR Newswire (Mar 12, 2013)
Cardiome announces settlement of debt and termination of line of credit with Merck

PR Newswire (Mar 4, 2013)
Cardiome Selects Quintiles To Manage Global Regulatory Affairs And Life Cycle Safety Activities For BRINAVESS™ (Vernakalant Intravenous)

PR Newswire (Feb 4, 2013)
Cardiome Reaches Agreement With Merck to Retire Debt and Close Line of Credit

GlobeNewswire (Dec 11, 2012)
Cardiome Reports Third Quarter Results

GlobeNewswire (Nov 13, 2012)
NASDAQ Grants Cardiome 180 Day Extension to Regain Compliance With Bid Price Requirement

GlobeNewswire (Oct 31, 2012)
NASDAQ Approves Cardiome's Request to Transfer Its Listing to The NASDAQ Capital Market

GlobeNewswire (Oct 25, 2012)
Cardiome to Hold Conference Call

GlobeNewswire (Sep 26, 2012)
Merck Returns Global Marketing and Development Rights for Vernakalant to Cardiome

GlobeNewswire (Sep 26, 2012)
Cardiome Announces Appointment of Jennifer Archibald as Chief Financial Officer

GlobeNewswire (Sep 20, 2012)
Cardiome Notes Updated Guidelines From European Society of Cardiology Now Include Brinavess(TM) (Vernakalant) for Infusion

GlobeNewswire (Sep 10, 2012)
Cardiome to Hold Investor Update Call

GlobeNewswire (Aug 21, 2012)
Cardiome Reports Second Quarter Results

GlobeNewswire (Aug 7, 2012)
Cardiome Announces Workforce Reduction

GlobeNewswire (Jul 9, 2012)

CRME vs. ETF Alternatives

Company Description

Currently, there's no company description for CRME.

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: Canada

All
| Earnings
| Dividends
| M&A
| On the move

Monday, May 13, 9:22 AM Cardiome (CRME): Q1 EPS of $1.47 misses by $0.01. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, April 19, 1:09 PM Midday top 10 gainers: VRTX +60%. NETE +33%. RH +21%. MCOX +18%. OSTK +17%. HWAY +17%. NVDQ +16%. ANAC +12%. LIVE +11%. CMG +10%.
Midday top 10 losers: ACTG -25%. VIMC -15%. PRGX -14%. AIRM -14%. NSIT -12%. CNIT -11%. RMBS -10%. CRME -10%. DIT -9%. OSH -9%. 1 Comment [On the Move]
Friday, March 15, 1:37 PM Cardiome Pharma (CRME -3.8%) suffers a bout of profit-taking today after its Q4 beat on a per share basis but came up far short on revenue as total sales plummeted 75% Y/Y. Net income was $7.7M , as compared to a net loss of $5.9M for Q411, with the increase largely due to an $11.2M gain on the settlement of debt owed to Merck. Comment! [Healthcare, Earnings, On the Move]
Friday, March 15, 7:23 AM Cardiome Pharma (CRME): Q4 EPS of -$0.13 misses by $0.03. Revenue of $100K misses by $740K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, March 15, 12:05 AM Notable earnings before Friday’s open: CRME, PGNX, ZGNX Comment! [Earnings]
Thursday, March 14, 5:30 PM Notable earnings before Friday’s open: CRME, PGNX, ZGNX Comment! [Earnings]
Tuesday, December 11, 2012, 10:48 AM Cardiome Pharma (CRME +41%) leaps higher out of an earlier trading halt after the company says it's reached a deal with Merck (MRK +0.6%) to settle its debt obligations stemming from it's collaboration on vernakalant - a treatment for atrial fibrillation - which it signed in April 2009. Under the terms of the settlement, CRME will pay MRK $20M to settle its outstanding debt of $50M, and MRK will terminate a $100M credit facility it had made available to CRME. Comment! [Healthcare, On the Move]
Wednesday, September 26, 2012, 2:17 PM Cardiome Pharma ([[CRME] +4.2%) trades up on the back of Merck's ([[MRK] +0.5%) announcement that it will return the global marketing and development rights for both the intravenous and oral formulations for vernakalant to CRME. Comment! [Healthcare, On the Move]
Friday, September 21, 2012, 10:53 AM Shares of Cardiome Pharma (CRME +3.2%) move higher after announcing the appointment of Jennifer Archibald as CFO, following the resignation of Curtis Sikorsky. Mr. Sikorsky plans to remain on in a consulting role to assist during the transition. 1 Comment [Healthcare, On the Move]
Monday, March 19, 2012, 9:45 AM Shares of Cardiome Pharma (CRME -43%) plunge after announcing Merck (MRK) will stop development of its oral vernakalant, which was being evaluated as maintenance therapy for the long-term prevention of atrial fibrillation recurrence. Comment! [Healthcare, On the Move]
Friday, November 11, 2011, 2:26 PM Cardiome Pharma (CRME -7%) gets hit after Wedbush cuts the shares to Neutral, citing concern over continued delays in the Phase 3 trials for oral Vernakalant by its partner Merck. Comment! [Healthcare, On the Move]
Tuesday, July 26, 2011, 11:14 AM Canadian drug developer Cardiome Pharma (CRME) surges 23.5% after announcing it has given consent for the transfer of North American rights for the development and commercialization of its Vernakalant IV atrial fibrillation drug from Astellas (ALPMY.PK) to Merck (MRK). Cardiome releases earnings after the close today. Comment! [Healthcare, On the Move]
Friday, July 8, 2011, 11:31 AM Sanofi (SNY +0.5%) discontinues Phase III trials of its atrial fibrillation drug Multaq, leaving competitor Cardiome's (CRME +2.5%) own recently approved oral antiarrhythmic Vernakalant open to gain market share. Comment! [Healthcare]
Thursday, October 21, 2010, 9:22 AM Cardiome Pharma (CRME) says a key Phase III clinical trial for its cardiac drug KYNAPID has been halted due to safety concerns. The clinical trial is being run by Cardiome's development partner, Japanese drug maker Astellas (ALPMY). CRME -21.3% premarket. (PR) 1 Comment
Thursday, October 21, 2010, 9:05 AM Premarket gainers: WSTL +20%. XING +14%. NFLX +11%. PTEC +9%. EBAY +8%. MNTA +7%. ABK +6%. ALXN +5%. CTIC +5%. IRE +4%. AVII +4%. NOK +4%.
Losers: CRME -25%. CRUS -12%. PLCE -12%. SHZ -8%. MLNX -5%. ADS -5%. REE -4%. CYS -4%. Comment!
Thursday, September 2, 2010, 9:00 AM Premarket gainers: OREX +27%. BKC +21%. CRME +12%. RNN +12%. CERS +8%. CTIC +5%. WEN +4%. MPEL +4%.
Losers: PSS -6%. Comment!

CRME Cardiome Pharma Corporation

CRME

Cardiome Pharma Corporation